#EULAR2026 POS0438 In Part A (Phase II) RCT of Cutaneous #lupus, Litifilimab, a BDCA2 mAb improved CLASI-A vs PBO at Week 16. -Improvement as early as Week 4 -Low viral infections. Common AE: nasopharyngitis & headache. -Interested to see results of Part B (phase III) @RheumNow https://t.co/2zzHd9NgBi